Arrowstreet Capital Limited Partnership Buys 96,445 Shares of Encompass Health Corporation $EHC

Arrowstreet Capital Limited Partnership raised its stake in Encompass Health Corporation (NYSE:EHC) by 9.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,163,834 shares of the company’s stock after acquiring an additional 96,445 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Encompass Health were worth $123,529,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. increased its stake in shares of Encompass Health by 3,059,159.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock valued at $402,640,000 after buying an additional 3,793,358 shares during the period. AlphaCore Capital LLC acquired a new position in shares of Encompass Health during the fourth quarter valued at $4,881,000. JPMorgan Chase & Co. boosted its holdings in Encompass Health by 5.3% in the third quarter. JPMorgan Chase & Co. now owns 1,410,335 shares of the company’s stock valued at $179,141,000 after acquiring an additional 70,387 shares during the last quarter. Tudor Investment Corp ET AL increased its position in Encompass Health by 155.3% in the third quarter. Tudor Investment Corp ET AL now owns 210,712 shares of the company’s stock worth $26,765,000 after purchasing an additional 128,191 shares during the period. Finally, SG Americas Securities LLC increased its position in Encompass Health by 1,070.9% in the fourth quarter. SG Americas Securities LLC now owns 88,054 shares of the company’s stock worth $9,346,000 after purchasing an additional 80,534 shares during the period. 97.25% of the stock is owned by institutional investors.

Encompass Health Stock Down 2.3%

Shares of NYSE:EHC opened at $99.13 on Tuesday. The company has a 50 day moving average price of $104.35 and a two-hundred day moving average price of $104.47. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.17 and a current ratio of 1.17. The company has a market capitalization of $9.83 billion, a PE ratio of 16.55, a PEG ratio of 2.21 and a beta of 0.72. Encompass Health Corporation has a 52 week low of $92.77 and a 52 week high of $127.99.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Thursday, April 30th. The company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.51 by $0.09. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the previous year, the business earned $1.37 EPS. The firm’s revenue was up 9.0% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Analysts forecast that Encompass Health Corporation will post 5.97 earnings per share for the current year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Wednesday, July 1st will be paid a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Wednesday, July 1st. Encompass Health’s payout ratio is presently 12.69%.

Analysts Set New Price Targets

EHC has been the topic of a number of research reports. Barclays cut their target price on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 5th. Weiss Ratings reissued a “buy (b-)” rating on shares of Encompass Health in a research note on Monday, June 8th. Leerink Partners set a $152.00 price objective on shares of Encompass Health in a report on Friday, May 22nd. Wall Street Zen raised shares of Encompass Health from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, TD Cowen assumed coverage on shares of Encompass Health in a research report on Thursday, May 28th. They set a “buy” rating and a $125.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Encompass Health has a consensus rating of “Buy” and an average target price of $143.86.

Insider Activity

In other news, EVP Patrick William Tuer sold 682 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $104.56, for a total transaction of $71,309.92. Following the sale, the executive vice president owned 24,755 shares of the company’s stock, valued at $2,588,382.80. This trade represents a 2.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.80% of the stock is owned by company insiders.

About Encompass Health

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.